Sign In
Buy NOVN
$0.0941
+0 (+0%)
At Close: Nov 20, 2023
Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
05:15am, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
Basel, April 6, 2022 — Sandoz today announces the extension and expansion until January 31, 2025 of its strategic collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge dig
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
12:29am, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
Basel, April 6, 2022 — Novartis today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and pediatric patien
Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility
05:15am, Tuesday, 05'th Apr 2022 GlobeNewswire Inc.
Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (FDA) has granted commercial licensure approval for its Durham, N.C. site, a multi-product gene therapy manufact
Is WisdomTree International High Dividend ETF (DTH) a Strong ETF Right Now?
10:20am, Monday, 04'th Apr 2022 Zacks Investment Research
Smart Beta ETF report for DTH
Novartis gibt neue Organisationsstruktur bekannt für schnelleres Wachstum, eine stärkere Pipeline und höhrere Produktivität
05:00am, Monday, 04'th Apr 2022 GlobeNewswire Inc.
Ad-hoc-Mitteilung gemäss Art. 53 KR
Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity
05:00am, Monday, 04'th Apr 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR
Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease
12:09pm, Friday, 25'th Mar 2022 GlobeNewswire Inc.
Basel, March 25, 2022 — Novartis announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending appr
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
12:03pm, Friday, 25'th Mar 2022 GlobeNewswire Inc.
Basel, March 25, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the Eur
Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer
08:19pm, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR
4 Penny Stocks Insiders Are Buying
12:54pm, Wednesday, 23'rd Mar 2022 Benzinga
The Dow Jones surged by more than 250 points on Tuesday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern a
Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce
06:15am, Monday, 14'th Mar 2022 GlobeNewswire Inc.
Basel, March 14, 2022 — Sandoz, a Novartis division, announced today that it has successfully acquired the UK-based medical and drug delivery device development company, Coalesce Product Development
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
11:00pm, Sunday, 13'th Mar 2022 GlobeNewswire Inc.
Basel, March 13, 2022 — Novartis today announced new data that reinforce the transformational benefit of Zolgensma® (onasemnogene abeparvovec), an essential one-time treatment for spinal muscular
Novan Acquires EPI Health To Bolster Commercial Force For Potential Marketing Of Its lead Products
04:10pm, Friday, 11'th Mar 2022 Benzinga
Novan Inc (NASDAQ: NOVN ) has acquired EPI Health LLC , a specialty pharmaceutical company focused on the U.S. dermatology market. EPI Health offers a product portfolio that includes four prescription products across psoriasis, rosacea, dermatosis, and acne, with a 2021 operating revenue of $17.6 million. Deal consideration of $27.5 million consists of $11.0 million in cash and $16.5 million in … Full story available on Benzinga.com
Novan acquires EPI Health for upfront payment of $27.5M and milestone payment of $23.5M
11:42am, Friday, 11'th Mar 2022 Seeking Alpha
Novan (NOVN) is acquiring EPI Health, LLC, a specialty pharmaceutical company focused on the U.S
Novan Acquires EPI Health, a Specialty Dermatology Company
11:35am, Friday, 11'th Mar 2022 GlobeNewswire Inc.
Acquisition Represents Forward Integration as a Commercial Organization Acquisition Represents Forward Integration as a Commercial Organization
